TransMedics at Stifel 2026 Healthcare Conference 2026: growth push widens

On November 10, 2026, TransMedics (TMDX) highlighted a comprehensive growth strategy during the Stifel 2026 Healthcare Conference. Management expressed optimism about clinical advancements and market expansion, yet they also admitted to challenges such as reimbursement restrictions, seasonal fluctuations, and the absence of 2027 guidance.

The company's heart and lung trials are advancing rapidly, with ENHANCE Part A enrolling 175 patients within seven to eight months. This rapid enrollment suggests strong market potential, with ENHANCE Part B and DENOVO aiming to access approximately 5,000 to 5,500 new U.S. cases annually, including around 3,500 lung and 2,200 heart cases.

Europe represents a significant growth opportunity for TransMedics, with revenue expected in the second half of 2027 and further growth anticipated in 2028. Kidney transplantation is identified as the most substantial long-term market opportunity, with notable clinical and cost-saving benefits. Service revenue is outpacing product revenue growth, but management anticipates convergence as new programs expand.

TransMedics is positioning itself as a transplant-enabling platform rather than solely a device provider. CEO Waleed Hassanein emphasized the company's focus on technology that enhances transplant outcomes and organ usage. The company employs a three-pronged growth strategy: OCS 2.0 for heart and lung transplants, European expansion via normothermic organ perfusion (NOP), and kidney transplantation, which is considered the largest market opportunity.

Heart and lung transplantation involves complex trials addressing organ edema, overnight preservation challenges, and the need for organ function enhancement. ENHANCE Part A has completed enrollment, while ENHANCE Part B and DENOVO are set to launch, targeting a combined 7,000 U.S. cases per year. Europe is a strategic priority, with management acknowledging the need to address country-specific reimbursement issues and logistical challenges.

The company aims to gain a foothold in Europe by the second half of 2027, with meaningful revenue expected in 2028. International revenue reached nearly $7 million in Q3 2026, with projections of approaching $10 million per quarter by the end of 2027. TransMedics anticipates a gradual shift in PAD charter revenue to organ-transplant-based revenue, with some slowdown expected in the first half of 2027.